Aplastic anemia

Current Opinion in Hematology

Volumn 15, Issue 3, 2008, Pages 162-168

  Young, Neal S ^a,b   Scheinberg, Phillip ^a   Calado, Rodrigo T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Bldg 10/CRC ^*  (United States)

Author keywords

Antithymocyte globulin; Aplastic anemia; Bone marrow failure; Cyclosporine; Pancytopenia; Stem cell transplantation

Indexed keywords

LEUKOCYTE ANTIGEN; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR T BET;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; APOPTOSIS; BONE MARROW DISEASE; CELL CLONE; CELL DESTRUCTION; CYTOTOXIC LYMPHOCYTE; DISEASE COURSE; GENE MUTATION; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR EVOLUTION; MYELODYSPLASIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL TIME; T LYMPHOCYTE;

ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 41949122374     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282fa7470     Document Type: Review

References (89)

1. Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford; 1991.
2. Issaragrisil S, Kaufman D, Anderson T, et al. The epidemiology of aplastic anemia in Thailand. Blood 2006; 107:1299-1307.
3. Hamerschlak N, Maluf E, Pasquini R, et al. Incidence of aplastic anemia and agranulocytosis in Latin America: the LATIN study. Sao Paulo Medical Journal 2005; 123:101-104.
4. Young NS. Drugs and chemicals. In: Young NS, Alter BP, editors. Aplastic anemia, acquired and inherited. Philadelphia, PA: W.B. Saunders; 1994 . pp. 100-132.
5. Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant- induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 1983; 61:889-893.
6. Sutton JF, Stacey M, Kearsey SE, et al. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking GSTT1 gene. Pediatric Blood Cancer 2004; 42:122-126.
7. Dufour C, Syahn J, Bacigalupo A, et al. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1. GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica 2005; 90:1027-1031.
8. Lu J, Basu A, Melenhorst J, et al. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood 2004; 103:4588-4593.
9. Young NS. Hematopoietic cell destruction by immune mechanisms in aquired aplastic anemia. Semin Hematol 2000; 37:3-14.
10. Sloand EM, Kim S, Maciejewski JP, et al. Intracellular interferon- y in circulating and marrow T cells detected by flow cytometry and the response to imunosuppressive therapy in patients with aplastic anemia. Blood 2002; 100:1185-1191.
11. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is upregulated in T cells from patients with aplastic anemia. Blood 2006; 107:3983-3991.
12. Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR [beta]-CDR3 sequencing. The Lancet 2004; 364:355-364.
13. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007; 110:1603-1606. Regulatory T cells were decreased at presentation in almost all patients; a regulatory T-cell defect was implicated in autoimmune marrow failure as had been suggested by animal studies and in a few other human autoimmune diseases.
14. Chen J, Ellison FM, Eckhaus MA, et al. Minor antigen H60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol 2007; 178:4159-4168. In an immune-mediated murine model for aplastic anemia, a single minor histocompatibility mismatch triggered an immune response leading to massive bone marrow destruction. Immunosuppressive drug treatment or enhancement of regulatory T-cell function protected animals from the development of bone marrow failure.
15. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 1994; 84:4257-4261.
16. Maciejewski JP, Follmann D, Rivera CE, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and PNH/aplastic anemia syndrome. Blood 2001; 98:3513-3519.
17. Demeter J, Messer G, Schrezenmeier H. Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol 2002; 81:566-569.
18. Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol 2004; 126:682-685.
19. Gidvani V, Ramkissoon S, Sloand EM, Young NS. Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol 2007; 82:721-724.
20. Philpott NJ, Scopes J, Marsh JCW, et al. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol 1995; 23:1642-1648.
21. Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia. Br J Haematol 1997; 98:18-20.
22. Maciejewski JP, Selleri C, Sato T, et al. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. BR J Haematol 1995; 91:245-252.
23. Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004; 104:4210-4218.
24. Ball SE, Gibson FM, Rizzo S, et al. Progressive telomere shortening in aplastic anemia. Blood 1998; 91:3582-3592.
25. Brummendorf TH, Maciejewski JP, Young NS, Lansdorp PL. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001; 97:895-900.
26. Fogarty PF, Yamaguchi H, Wiestner A, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003; 362:1628-1630.
27. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352:1413-1424.
28. Knight SW, Heiss NS, Vulliamy TJ, et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999; 65:50-58.
29. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413:432-435.
30. Marrone A, Walne A, Tamary H, et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraa-Hreidarsson syndrome. Blood 2007; 110:4198-4205.
31. Du HY, Pumbo E, Manley P, et al. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood 2008; 111:1128-1130.
32. Calado RT, Graf SA, Wilkerson KL, et al. Mutations in the SBDS gene in acquired aplastic anemia. Blood 2007; 110:1141-1146. Heterozygosity for SBDS mutations previously described in Shwachman-Diamond syndrome, were identified in young patients with idiopathic acquired aplastic anemia.
33. Young NS. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep 2005; 4:103-109.
34. Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma 2004; 45:433-440.
35. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106:841-851.
36. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007; 109:2399-2405. Resistance to apoptosis underlies clonal expansion of CD34 cells from patients with trisomy 8 myelodysplastic syndrome.
37. Maciejewski JP, Risitano AM, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99:3129-3135.
38. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100:786-790.
39. Socie G, Mary J-Y, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109:2794-2796. In this retrospective study, an increased incidence of evolution to myelodysplasia and leukemia was observed in aplastic anemia patients who received initial immunosuppressive therapy with G-CSF compared with those who did not receive G-CSF with initial immunosuppression.
40. Sloand EM, Yong ASM, Ramkissoon S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci 2006; 103:14483-14488.
41. Sloand EM, Scheinberg P, Fenlon E, et al. Monosomy 7 detected by FISH at disease presentation is a marker for non-response to immunosuppression. ASH Annual Meeting Abstracts 2007; 110:506a.
42. Young NS, Alter BP. Aplastic anemia, acquired and inherited. Philadelphia, PA: Saunders; 1994.
43. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59:1194-1200.
44. Raefsky EL, Gascon P, Gratwohl A, et al. Biological and immunological characterization of ATG and ALG. Blood 1986; 68:712-719.
45. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Eng J Med 1991; 324:1297-1304.
46. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globuillin and cyclosporine. Semin Hematol 2000; 37:56-68.
47. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia. Association between hematologic response and long-term outcome. JAMA 2003; 289:1130-1135.
48. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globuilin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95:1931-1934.
49. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000; 96:2049-2054.
50. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmaier H. Antithymocyte globulin with or without cyclosporin A. 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101:1236-1242.
51. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005; 106:2102-2104.
52. Fuhrer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. Klinische Padiatrie 1998; 210:173-179.
53. Scheinberg P, Wu CO, Nunez O, Young NS. Long term outcome of pediatric patients with severe aplastic anemia treated with anti-thymocyte globulin and cyclosporine. ASH Annual Meeting Abstracts 2007; 110:505a.
54. Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109:3219-3224.
55. Thomas FT, Griesedieck C, Thomas J. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Transpl Proc 1984; 16:1561-1563.
56. + regulatory T cells in vitro. Blood 2008; 4 Feb [Epub ahead of print].
57. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999; 107:330-334.
58. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998; 100:393-400.
59. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133:622-627.
60. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993; 85:371-377.
61. Scheinberg P, Wu CO, Nunez O, Young NS. Marked Improvement in shortand long-term survival in severe aplastic anemia patients treated with immunosuppression in the past 18 years. ASH Annual Meeting Abstracts 2007; 110:506a.
62. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response and survival for severe aplastic anemia patients treated with immunosuppression. ASH Annual Meeting Abstracts 2007; 110:504a.
63. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133:606-611.
64. Jeng MR, Naidu PE, Rieman MD, et al. Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia. Pediatr Blood Cancer 2005; 45:170-175.
65. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119:1075-1082.
66. Tisdale JF, Dunn DE, Geller NL, et al. High-dose cyclophosphamide in severe aplastic anemia: a randomized trial. Lancet 2000; 356:1554-1559.
67. Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110:1756-1761. In this prospective randomized study comparing horse ATG+cyclosporine with or without G-CSF, no differences in the incidence of infections, clonal evolution or survival were observed between the two groups; however, a higher response rate and a lower relapse rate were observed in the G-CSF treated patients.
68. Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000; 111:321-328.
69. Howard SC, Naidu PE, Hu XJ, et al. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer 2004; 43:545-551.
70. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party. Blood 1999; 93:2191-2195.
71. Maciejewski JP, Sloand EM, Nunez O, et al. Recombinant humanized anti-IL-2 receptor antibody (Daclizumab) produces responses in patients with moderate aplastic anemia. Blood 2003; 102:3584-3586.
72. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin in Hematol 2000; 37:30-42.
73. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509-2519.
74. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91:3637-3645.
75. Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007; 370:427-438.
76. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007; 370:415-426.
77. Gomez-Almaguer D, Vela-Ojeda J, Jaime-Perez JC, et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience. Am J Hematol 2006; 81:157-161.
78. Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 2006; 133:305-314.
79. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109:4582-4585. In this prospective randomized study, conditioning with cyclophosphamide+ATG was not shown to be superior to cyclophosphamide alone in aplastic anemia patients.
80. Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110:1397-1400. In this retrospective study, aplastic anemia patients younger than 20 years of age had a higher incidence of chronic GVHD with peripheral blood progenitor mobilization compared with those who received a bone marrow graft.
81. Passweg JR, Perez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006; 37:641-649.
82. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan marrow Donor Program. Blood 2002; 100:799-805.
83. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 1999; 5:243-252.
84. Viollier R, Socie G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41:45-50. This retrospective study attributes the better outcome of unrelated donor transplantation in recent years to better supportive care, in particular the routine use of high molecular HLA typing for donor selection.
85. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12:1277-1284.
86. Maury S, Balere-Appert M-L, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92:589-596. This retrospective study shows that survival after unrelated stem-cell transplantation for SAA has improved significantly over the past 15 years. The better survival was attributed to better donor selection due to high-resolution HLA matching. Results for young patients who are fully HLA-matched at the allelic level with their donor were comparable to those observed after a matched sibling donor.
87. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108:1485-1491.
88. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and antithymocyte globulin for alternative donor tranplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005: 1-4.
89. Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111:1054-1059. This Japanese multicenter randomized study compares the efficacy of a repeat course of immunosuppression to an alternative donor HSCT as second-line therapy in children who are unresponsive to initial ATG. Although no survival difference was observed between the two groups, patients who underwent HSCT had a superior failure free survival (broadly defined by the authors as survival with response) compared to those who received a repeat course of immunosuppression.